Autophagy Inhibition Enhances the Antitumor Efficacy of MET Targeting in MET-High Pancreatic Cancer
Zhiyi Min, Chunbin Wang, Tongjin Yin, Wanyan Jiao, Dandan Zhou, Xuyao Zhang, Junli Cui, Zhe Ding · 2026
Read Autophagy Inhibition Enhances the Antitumor Efficacy of MET Targeting in MET-High Pancreatic Cancer by Zhiyi Min, Chunbin Wang, Tongjin Yin, Wanyan Jiao, Dandan Zhou, Xuyao Zhang, Junli Cui, Zhe Ding (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13591368.txt.
Description
Zhiyi Min and seven co-authors study pancreatic cancer with high levels of MET, in work published in 2026. They test savolitinib, a drug that blocks MET, in the cell lines AsPC-1 and BxPC-3. They also ask whether autophagy, the cell's own recycling process, helps cancer cells survive that block.
Savolitinib lowered cell growth and raised cell death, while also turning on autophagy by cutting AKT and mTOR signals. Adding chloroquine, which blocks autophagy, made the drug work much better in cells and in mouse tumors. The team reads autophagy as a protective response and argues that blocking both paths merits more testing.
Catalog record
| CREATOR | Zhiyi Min, Chunbin Wang, Tongjin Yin, Wanyan Jiao, Dandan Zhou, Xuyao Zhang, Junli Cui, Zhe Ding |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |